Changeflow GovPing Pharma & Drug Safety Macrocyclic CFTR Modulators for Cystic Fibrosis
Routine Rule Added Final

Macrocyclic CFTR Modulators for Cystic Fibrosis

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

USPTO published patent application US20260098060A1 for macrocyclic CFTR modulators for treating cystic fibrosis. The application covers compounds of Formula (I), their preparation, pharmaceutical salts, and uses as CFTR modulators or in combination with CFTR potentiators/correctors. Inventors include Martin Bolli, Christine Brotschi, John Gatfield, and others. The application was filed on September 14, 2023.

What changed

USPTO published patent application US20260098060A1 for macrocyclic CFTR modulators used in cystic fibrosis treatment. The application covers compounds of Formula (I), their preparation, pharmaceutical salts, and uses as CFTR modulators or in combination with CFTR potentiators/correctors.

Patent application publication provides public notice of the invention's scope, allowing competitors to assess freedom to operate and design-around opportunities. Pharmaceutical companies developing CFTR-targeted therapies should monitor the application's prosecution through grant.

What to do next

  1. Monitor for patent grant status
  2. Review claims for freedom to operate analysis

Archived snapshot

Apr 11, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

MACROCYCLIC CFTR MODULATORS

Application US20260098060A1 Kind: A1 Apr 09, 2026

Inventors

Martin BOLLI, Christine BROTSCHI, John GATFIELD, Nicolaas Johannes HAUWERT, Hervé SIENDT, Clemens WAGNER, Anita WEGERT, Jodi T. WILLIAMS

Abstract

The present invention relates to macrocyclic compounds of Formula (I) wherein Ar1, Ar2, R1, R2, R3, R4, and X are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), to their use as modulators of CFTR alone or in combination with one or more therapeutically active ingredients acting as CFTR potentiators or CFTR correctors.

CPC Classifications

C07K 7/64 A61K 38/00

Filing Date

2023-09-14

Application No.

19112147

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260098060A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application publication CFTR modulator compounds Pharmaceutical compositions
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!